Pentasomy 8q in therapy-related myelodysplastic syndrome due to cyclophosphamide therapy for fibrosing alveolitis.
Cancer Genet Cytogenet
; 141(1): 79-82, 2003 Feb.
Article
en En
| MEDLINE
| ID: mdl-12581903
ABSTRACT
Trisomy 8/8q is a common cytogenetic event in myelocytic malignancies, ranging from myelodysplastic syndrome (MDS) to acute myelocytic leukemia (AML) to blastic transformation of chronic myelocytic leukemia. Isochromosome 8q results in the same gene dosage effect. Duplication of i(8q), resulting in pentasomy 8q, has been reported only in two cases of AML. A patient with fibrosing alveolitis on prolonged cyclophosphamide treatment developed therapy-related MDS. Karyotyping, FISH, and CGH analysis showed a duplicated i(8q) among other complex abnormalities. The clinical features of 11 cases of myelocytic leukemia with pentasomy and hexasomy 8/8q were summarized. Compared with trisomy and tetrasomy 8, significant features included reduced median survival (90 days), treatment refractoriness (even with transplantation), monocytic differentiation, trilineage dysplasia, and radiation or toxin exposure. Increasing copy numbers of chromosome 8/8q may therefore be a marker of advanced leukemic evolution, exposure to toxins, underlying myelodysplasia, and an overall poor prognosis.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Fibrosis Pulmonar
/
Síndromes Mielodisplásicos
/
Cromosomas Humanos Par 8
/
Ciclofosfamida
Tipo de estudio:
Prognostic_studies
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
Cancer Genet Cytogenet
Año:
2003
Tipo del documento:
Article
País de afiliación:
China